sellWeak cluster of 410b5-1 plan
Matsuda Masaru sold $17k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 1,775 shares at an average of $9.68, traded Nov 19, 2024, filed Nov 19, 2024.
Warning score
10Value
$17k
1,775 shares
Holdings after
181,373
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001787306-24-000159, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | AGrant or award Common Stock10b5-1 | +4,875 | $0.00 | $0 | 183,148 | Nov 19, 2024 |
| Nov 19, 2024 | SOpen-market sale Common Stock10b5-1 | -1,775 | $9.68 | $17k | 181,373 | Nov 19, 2024 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 3Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $24k | 1,691 | |
| 16Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Watanabe Todd Franklin See Remarks | $228k | 15,000 | |
| 18Weak | buy 2 | ARQT Arcutis Biotherapeutics, Inc. | Watanabe Todd Franklin See Remarks | $21k | 6,038 | |
| 21Weak | sell 310b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Welgus Howard G. director | $125k | 10,000 | |
| 23Weak | buy 2 | ARQT Arcutis Biotherapeutics, Inc. | Matsuda Masaru See Remarks | $19k | 5,657 | |
| 10Weak | buy | ARQT Arcutis Biotherapeutics, Inc. | Edwards Larry Todd See Remarks | $7,767 | 1,093 | |
| 31Weak | sell 4 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $163k | 16,023 | |
| 46Moderate | sell 5 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $713k | 69,226 | |
| 50Moderate | sell 5 | ARQT Arcutis Biotherapeutics, Inc. | Curran Terrie director | $94k | 8,687 | |
| 21Weak | sell 510b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $134k | 15,441 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.